Nasdaq11d
Milestone Pharmaceuticals Reports FDA PDUFA Review Date for CARDAMYST™ Nasal Spray Targeting PSVT, Plans for Mid-2025 Launch
Milestone Pharmaceuticals Inc. announced that the FDA has set a PDUFA review goal date of March 27, 2025, for its nasal spray CARDAMYST™ (etripamil), aimed at treating Paroxysmal ...
Business Insider12d
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) Assuming FDA approval, proposed launch in PSVT targeted for ...
11 Things That Can Freshen Even The Stinkiest Breath, According To Reviews And Dentists
Rated 4.8 out of 5 stars on Amazon, these pocket-sized strips pack a powerful, nose-clearing punch that can do wonders for ...
CHOICE13d
Illegal tanning nasal sprays pushed by social media influencers
Influencers promoting tanning nasal sprays are popping up on the social media feeds of people around the world, especially ...
Equities Analysts Issue Forecasts for SPRY FY2028 Earnings
Research analysts at Leerink Partnrs dropped their FY2028 EPS estimates for ARS Pharmaceuticals in a research note issued to ...
26 easily overlooked health essentials to pack for spring break travel, according to doctors and pharmacists
Don't let your spring break travel get ruined by illness or injury. Be prepared with these easily overlooked health ...
Expert Outlook: Emergent BioSolutions Through The Eyes Of 5 Analysts
Analysts have recently evaluated Emergent BioSolutions and provided 12-month price targets. The average target is $15.0, ...
Clinical Advisor7d
Nocturnal Mouth-Taping Shows Promise for Sleep Apnea
Researchers reviewed the literature on nocturnal mouth-taping and evaluated claims made on TikTok about the benefits of mouth-taping during sleep.